OncoMatch/Clinical Trials/NCT05045950
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Is NCT05045950 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Memantine -Twice Daily or Extended Release for brain metastases.
Treatment: Memantine -Twice Daily or Extended Release — Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cranial whole brain radiation therapy
Prior cranial whole brain radiation therapy
Lab requirements
Kidney function
creatinine clearance is ≥ 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
- Clement J. Zablocki Veterans Affairs Medical Center · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05045950 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cranial whole brain radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify